Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) have been given an average recommendation of “Moderate Buy” by the nine analysts that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating, four have given a buy rating and two have assigned a strong buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $91.8333.

A number of equities analysts have recently commented on the stock. The Goldman Sachs Group reissued a “neutral” rating and issued a $68.00 target price on shares of Tarsus Pharmaceuticals in a research note on Thursday, February 5th. Guggenheim upped their price target on shares of Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Lifesci Capital upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Monday, March 16th. Wall Street Zen lowered Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, Zacks Research cut Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 25th.

Tarsus Pharmaceuticals Stock Down 0.6%

Shares of NASDAQ:TARS opened at $64.13 on Thursday. The stock has a 50-day simple moving average of $68.89 and a 200-day simple moving average of $70.44. The stock has a market capitalization of $2.73 billion, a P/E ratio of -39.59 and a beta of 0.55. Tarsus Pharmaceuticals has a 1 year low of $38.51 and a 1 year high of $85.25. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.82 and a current ratio of 3.85.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings results on Monday, February 23rd. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The business had revenue of $151.67 million during the quarter, compared to analysts’ expectations of $144.56 million. Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. Equities analysts forecast that Tarsus Pharmaceuticals will post -3.17 earnings per share for the current year.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, insider Jeffrey S. Farrow sold 2,186 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Thursday, March 19th. The shares were sold at an average price of $67.00, for a total transaction of $146,462.00. Following the sale, the insider owned 43,316 shares in the company, valued at $2,902,172. This trade represents a 4.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, General Counsel Bryan Wahl sold 4,231 shares of the business’s stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $67.00, for a total transaction of $283,477.00. Following the transaction, the general counsel directly owned 63,959 shares in the company, valued at approximately $4,285,253. The trade was a 6.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 85,391 shares of company stock worth $5,927,095. Insiders own 8.97% of the company’s stock.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Tarsus Pharmaceuticals by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,143 shares of the company’s stock worth $1,137,000 after buying an additional 1,217 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Tarsus Pharmaceuticals by 2.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,220 shares of the company’s stock valued at $3,659,000 after acquiring an additional 1,394 shares in the last quarter. Jane Street Group LLC grew its stake in shares of Tarsus Pharmaceuticals by 105.8% during the first quarter. Jane Street Group LLC now owns 10,456 shares of the company’s stock valued at $537,000 after acquiring an additional 190,000 shares in the last quarter. Envestnet Asset Management Inc. increased its position in shares of Tarsus Pharmaceuticals by 15.9% during the second quarter. Envestnet Asset Management Inc. now owns 10,356 shares of the company’s stock worth $420,000 after acquiring an additional 1,418 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Tarsus Pharmaceuticals by 8.0% during the second quarter. Geode Capital Management LLC now owns 934,420 shares of the company’s stock worth $37,859,000 after acquiring an additional 68,986 shares during the last quarter. 90.01% of the stock is owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.